Upgrade Now

Alexander David Investments (ADI)

All online trades £12.50 plus an annual Management Fee of £35 & VAT with Selftrade. Apply

0.23p
   
  • Change Today:
    -0.010p
  • 52 Week High: 1.25
  • 52 Week Low: 0.080
  • Currency: UK Pounds
  • Shares Issued: 401.06m
  • Volume: 2,288,406
  • Market Cap: £0.92m
  • RiskGrade: 43
  • Beta: 0.87

USA Sales Update

RNS Number : 2857E
ReGen Therapeutics PLC
17 December 2009
 

For Immediate Release                                                                                       17 December 2009



ReGen Therapeutics Plc ('ReGen' or 'the Company')


USA SALES UPDATE



ReGen Therapeutics Plc (AIM:RGT) are pleased to announce that the Company has received today a further order from Metagenics Inc. its distributor in the professional channel in the USA.


The Board are making this announcement in view of the fact that the USA is a key market for ReGen and the positive response by shareholders to the marketing information contained in the General Meeting Statement announced on the 7 December. The size of the order is covered by commercial confidentiality. It is however significant to ReGen as it confirms Metagenics continuing commitment to the future of Colostrinin™ based products. This emphasises the point we made in our General Meeting Statement about Metagenics planned relaunch in North America during 2010.  


For further information please contact:

Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920


Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396

Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820 


  


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAILFLIFFLDLIA

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Top of Page